EyePoint, Inc.
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company leverages its proprietary bioerodible Durasert E technology platform for sustained intraocular drug delivery, enabling… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What EyePoint, Inc. does
In the company’s own words
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company leverages its proprietary bioerodible Durasert E technology platform for sustained intraocular drug delivery, enabling consistent therapeutic release over extended periods through a single intravitreal injection administered in a physician's office.
The company's lead product candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert E delivery system to target vascular endothelial growth factor-mediated retinal diseases. DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema, representing the two largest retinal disease markets. The company completed enrollment in its wet AMD Phase 3 trials, LUGANO and LUCIA, with topline data anticipated in mid-2026. The first patient was dosed in the Phase 3 DME program in February 2026. The company's pipeline also includes EYP-2301, razuprotafib formulated in Durasert E, in preclinical development for serious retinal diseases.
EyePoint's Durasert technology has been safely administered to thousands of patient eyes across four FDA-approved products. The bioerodible Durasert E formulation allows for higher drug payload delivery with complete bioabsorption, eliminating the need for surgical removal. Vorolanib's multi-mechanism of action addresses vascular permeability through VEGF receptor inhibition while providing anti-inflammatory effects through IL-6 and JAK-1 pathway inhibition, differentiating DURAVYU from existing anti-VEGF ligand-blocking therapies.
The company maintains manufacturing facilities in Watertown and Northbridge, Massachusetts, with a state-of-the-art facility in Northbridge supporting potential commercial launch preparations. EyePoint has established licensing agreements with Equinox Science for vorolanib intellectual property and with Betta Pharmaceuticals for Greater China commercialization rights. The company reported cash, cash equivalents, and marketable securities of $306.1 million as of December 31, 2025, providing funding runway into the fourth quarter of 2027. More information is available at www.eyepointpharma.com.
Company details
- Sector
- Healthcare
- Industry
- Medical Instruments
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1314102
- SIC
- 3826
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns EyePoint, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · EyePoint, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do EyePoint, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of EyePoint, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in EyePoint, Inc.'s last four quarterly filings that the numbers alone won't show?”